Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry

Angiogenesis

Volumn 13, Issue 3, 2010, Pages 251-258

  Sottnik, Joseph L ^a   Guth, Amanda M ^a   Mitchell, Leah A ^a   Dow, Steven W ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Blood vessel; Cancer; Endothelial; Immunohistochemistry; Microvessel density

Indexed keywords

CD31 ANTIGEN; VANDETANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTIGEN DETECTION; ARTICLE; ASPIRATION BIOPSY; CELL DENSITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; REPEAT PROCEDURE; REPRODUCIBILITY; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOPSY, FINE-NEEDLE; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MICE; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS;

MUS;

EID: 78149412844     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9182-0     Document Type: Article

References (20)

1. N Bouck V Stellmach SC Hsu 1996 How tumors become angiogenic Adv Cancer Res 69 135 174 1:CAS:528:DyaK28XlvFWiu74%3D 10.1016/S0065-230X(08)60862-3 8791681
2. J Folkman 1975 Tumor angiogenesis: a possible control point in tumor growth Ann Intern Med 82 96 100 1:STN:280:DyaE2s7otVSlsg%3D%3D 799908
3. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
4. CA Staton MW Reed NJ Brown 2009 A critical analysis of current in vitro and in vivo angiogenesis assays Int J Exp Pathol 90 195 221 1:CAS:528: DC%2BD1MXotV2ju7s%3D 10.1111/j.1365-2613.2008.00633.x 19563606
5. PB Vermeulen G Gasparini SB Fox, et al. 1996 Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation Eur J Cancer 32A 2474 2484 1:STN:280:DyaK2s3ht1Crsg%3D%3D 10.1016/S0959-8049(96)00379-6 9059336 (Pubitemid 27080786)
6. W Cai G Niu X Chen 2008 Imaging of integrins as biomarkers for tumor angiogenesis Curr Pharm Des 14 2943 2973 1:CAS:528:DC%2BD1MXmt1ehsQ%3D%3D 10.2174/138161208786404308 18991712
7. N Charnley S Donaldson P Price 2009 Imaging angiogenesis Methods Mol Biol 467 25 51 1:CAS:528:DC%2BD1MXhslyqt7w%3D 10.1007/978-1-59745-241-0-2 19301663
8. JD Pearlman RJ Laham M Post, et al. 2002 Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis Curr Pharm Des 8 1467 1496 1:CAS:528:DC%2BD38XkvVWksrw%3D 10.2174/1381612023394395 12052207 (Pubitemid 34693064)
9. CI Baeten J Wagstaff IC Verhoeven, et al. 2002 Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment Br J Cancer 87 344 347 1:STN:280: DC%2BD38vitFemtA%3D%3D 10.1038/sj.bjc.6600457 12177806
10. DL Gustafson EL Bradshaw-Pierce AL Merz, et al. 2006 Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing J Pharmacol Exp Ther 318 872 880 1:CAS:528:DC%2BD28XnslOlt7g%3D 10.1124/jpet.106.102376 16644900 (Pubitemid 44061263)
11. T Troiani NJ Serkova DL Gustafson, et al. 2007 Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model Clin Cancer Res 13 6450 6458 1:CAS:528:DC%2BD2sXht1CgtbzL 10.1158/1078-0432.CCR-07-1094 17975157 (Pubitemid 350075035)
12. ML Hermiston Z Xu A Weiss 2003 CD45: a critical regulator of signaling thresholds in immune cells Annu Rev Immunol 21 107 137 1:CAS:528: DC%2BD3sXjtF2ju7c%3D 10.1146/annurev.immunol.21.120601.140946 12414720 (Pubitemid 37174528)
13. ML Hermiston J Zikherman JW Zhu 2009 CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells Immunol Rev 228 288 311 1:CAS:528:DC%2BD1MXhsFGls7vK 10.1111/j.1600-065X.2008. 00752.x 19290935
14. ML Thomas L Lefrancois 1988 Differential expression of the leucocyte-common antigen family Immunol Today 9 320 326 1:CAS:528: DyaL1cXmt1yjsrw%3D 10.1016/0167-5699(88)91326-6 2978372
15. JL Wautier MP Wautier 2001 Blood cells and vascular cell interactions in diabetes Clin Hemorheol Microcirc 25 49 53 1:CAS:528:DC%2BD38XnsVWgsg%3D%3D 11790870
16. DE Jackson 2003 The unfolding tale of PECAM-1 FEBS Lett 540 7 14 1:CAS:528:DC%2BD3sXislCitLs%3D 10.1016/S0014-5793(03)00224-2 12681475 (Pubitemid 36398025)
17. SJ Kim JS Kim J Papadopoulos, et al. 2009 Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis Am J Pathol 174 1972 1980 1:CAS:528:DC%2BD1MXlvVWms7c%3D 10.2353/ajpath.2009.080819 19349357
18. J Drevs MA Konerding T Wolloscheck, et al. 2004 The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma Angiogenesis 7 347 354 1:CAS:528:DC%2BD2MXktVajtLs%3D 10.1007/s10456-005-1394-3 15886878 (Pubitemid 40767936)
19. MF McCarty J Wey O Stoeltzing, et al. 2004 ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer Mol Cancer Ther 3 1041 1048 1:CAS:528:DC%2BD2cXnsFajt70%3D 15367698
20. SR Wedge DJ Ogilvie M Dukes, et al. 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655 1:CAS:528:DC%2BD38XmsVShsL8%3D 12183421